The European Patent Office (EPO) has granted patent EP3699284B1, which concerns the role of U1 snRNP in regulating gene expression and modulating oncogenicity. The patent, with an effective date of March 18, 2026, lists Gideon Dreyfuss and others as inventors and covers various IPC classifications related to gene expression and therapeutic applications.

This grant signifies a new intellectual property right in the field of biotechnology and cancer research. While not imposing direct compliance obligations on regulated entities, it highlights areas of innovation that may lead to future drug development or therapeutic strategies. Companies operating in the pharmaceutical and biotech sectors should be aware of this patent as it pertains to their research and development activities, particularly concerning gene regulation and oncology.